Zacks Investment Research cut shares of Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) from a buy rating to a hold rating in a research note released on Wednesday morning.
According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “
Several other equities research analysts have also commented on the stock. HC Wainwright reaffirmed a buy rating on shares of Asterias Biotherapeutics in a report on Wednesday. ValuEngine lowered shares of Asterias Biotherapeutics from a hold rating to a sell rating in a research note on Monday, September 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of Hold and an average price target of $9.19.
Asterias Biotherapeutics (NYSEAMERICAN AST) opened at $2.45 on Wednesday. Asterias Biotherapeutics has a 12-month low of $2.00 and a 12-month high of $5.45.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.